Interferon alfa regulated gene expression in patients initiating interferon treatment for chronic hepatitis C

Hepatology

Volumn 37, Issue 3, 2003, Pages 610-621

  Ji, Xuhuai ^a,b   Cheung, Ramsey ^a,b   Cooper, Stewart ^c   Li, Qingqin ^e   Greenberg, Harry B ^a,b,d   He, Xiao Song ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MEDIMMUNE   (United States)

^e ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON;

ADULT; AGED; ANTIGEN PRESENTATION; ANTIVIRAL ACTIVITY; ARTICLE; CELL FUNCTION; CLINICAL ARTICLE; DNA MICROARRAY; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; HEPATITIS C; HUMAN; MONONUCLEAR CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME; UNINDEXED SEQUENCE; VIRUS IMMUNITY;

EID: 0037369731     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2003.50105     Document Type: Article

References (42)

1. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1485-1492.
2. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-965.
3. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982.
4. Samuel CE. Antiviral actions of interferons. Clin Microbiol Rev 2001;14:778-809.
5. Schena M, Shalon D, Davis RW, Brown PO. Quantitative monitoring of gene expression patterns with a complementary DNA microarray [see comments]. Science 1995;270:467-470.
6. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 1998;95:14863-14868.
7. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001;98:5116-5121.
8. Wang E, Miller LD, Ohnmacht GA, Liu ET, Marincola FM. High-fidelity mRNA amplification for gene profiling. Nat Biotechnol 2000;18:457-459.
9. Eisen MB, Brown PO. DNA arrays for analysis of gene expression. Methods Enzymol 1999;303:179-205.
10. Sherlock G, Hernandez-Boussard T, Kasarskis A, Binkley G, Matese JC, Dwight SS, Kaloper M, et al. The Stanford Microarray Database. Nucleic Acids Res 2001;29:152-155.
11. Radwanski E, Perentesis G, Jacobs S, Oden E, Affrime M, Symchowicz S, Zampaglione N. Pharmacokinetics of interferon alpha-2b in healthy volunteers. J Clin Pharmacol 1987;27:432-435.
12. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998;282:103-107.
13. Layden TJ, Mika B, Wiley TE. Hepatitis C kinetics: mathematical modeling of viral response to therapy. Semin Liver Dis 2000;20:173-183.
14. Der SD, Zhou A, Williams BR, Silverman RH. Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc Natl Acad Sci U S A 1998;95:15623-15628.
15. de Veer MJ, Holko M, Frevel M, Walker E, Der S, Paranjape JM, Silverman RH, et al. Functional classification of interferon-stimulated genes identified using microarrays. J Leukoc Biol 2001;69:912-920.
16. Khodursky AB, Peter BJ, Cozzarelli NR, Botstein D, Brown PO, Yanofsky C. DNA microarray analysis of gene expression in response to physiological and genetic changes that affect tryptophan metabolism in Escherichia coli. Proc Natl Acad Sci U S A 2000;97:12170-12175.
17. York IA, Goldberg AL, Mo XY, Rock KL. Proteolysis and class I major histocompatibility complex antigen presentation. Immunol Rev 1999;172:49-66.
18. Reinheckel T, Deussing J, Roth W, Peters C. Towards specific functions of lysosomal cysteine peptidases: phenotypes of mice deficient for cathepsin B or cathepsin L. Biol Chem 2001;382:735-741.
19. Janeway CA Jr, Bottomly K. Signals and signs for lymphocyte responses. Cell 1994;76:275-285.
20. Butcher EC, Picker LJ. Lymphocyte homing and homeostasis. Science 1996;272:60-66.
21. Trapani JA, Davis J, Sutton VR, Smyth MJ. Proapoptotic functions of cytoroxic lymphocyte granule constituents in vitro and in vivo. Curr Opin Immunol 2000;12:323-329.
22. Tough DF, Sun S, Zhang X, Sprent J. Stimulation of naive and memory T cells by cytokines. Immunol Rev 1999;170:39-47.
23. Marrack P, Kappler J, Mitchell T. Type I interferons keep activated T cells alive. J Exp Med 1999;189:521-530.
24. Yang CH, Murti A, Pfeffer SR, Basu L, Kim JG, Pfeffer LM. IFNalpha/beta promotes cell survival by activating NF-kappa B. Proc Natl Acad Sci U S A 2000;97:13631-13636.
25. Cooper S, Erickson AL, Adams EJ, Kansopon J, Weiner AJ, Chien DY, Houghton M, et al. Analysis of a successful immune response against hepatitis C virus. Immunity 1999;10:439-449.
26. Valiante NM, D'Andrea A, Crotta S, Lechner F, Klenerman P, Nuti S, Wack A, et al. Life, activation and death of intrahepatic lymphocytes in chronic hepatitis C. Immunol Rev 2000;174:77-89.
27. Guidotti LG, Chisari FV. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol 2001;19:65-91.
28. He XS, Greenberg HB. CD8+ T-cell response against hepatitis C virus. Viral Immunol 2002;15:121-131.
29. Samuel CE. Antiviral actions of interferon. Interferon-regulated cellular proteins and their surprisingly selective antiviral activities. Virology 1991;183:1-11.
30. Samuel CE. The eIF-2 alpha protein kinases, regulators of translation in eukaryotes from yeasts to humans. J Biol Chem 1993;268:7603-7606.
31. Kerr IM. The 2-5A system: a personal view. J Interferon Res 1987;7:505-510.
32. Player MR, Torrence PF. The 2-5A system: modulation of viral and cellular processes through acceleration of RNA degradation. Pharmacol Ther 1998;78:55-113.
33. Arnheiter H, Frese M, Kambadur R, Meier E, Haller O. Mx transgenic mice - animal models of health. Curr Top Microbiol Immunol 1996;206:119-147.
34. Haller O, Frese M, Kochs G. Mx proteins: mediators of innate resistance to RNA viruses. Rev Sci Tech 1998;17:220-230.
35. Cattaneo R. Biased (A - >I) hypermutation of animal RNA virus genomes. Curr Opin Genet Dev 1994;4:895-900.
36. Maas S, Rich A. Changing genetic information through RNA editing. Bioessays 2000;22:790-802.
37. Blight KJ, Kolykhalov AA, Rice CM. Efficient initiation of HCV RNA replication in cell culture. Science 2000;290:1972-1974.
38. Radaeva S, Jaruga B, Hong F, Kim WH, Fan S, Cai H, Strom S, et al. Interferon-alpha activates multiple STAT signals and down-regulates cMet in primary human hepatocytes. Gastroenterology 2002;122:1020-1034.
39. Siegal FP, Kadowaki N, Shodell M, Fitzgerald-Bocarsly PA, Shah K, Ho S, Antonenko S, et al. The nature of the principal type 1 interferon-producing cells in human blood. Science 1999;284:1835-1837.
40. Foster GR, Germain C, Jones M, Lechler RI, Lombardi G. Human T cells elicit IFN-alpha secretion from dendritic cells following cell to cell interactions. Eur J Immunol 2000;30:3228-3235.
41. Paul WE, Seder RA. Lymphocyte responses and cytokines. Cell 1994;76:241-251.
42. Hu KQ, Vierling JM, Redeker AG. Viral, host and interferon-related factors modulating the effect of interferon therapy for hepatitis C virus infection. J Viral Hepat 2001;8:1-18.